How Food, Gut Bacteria, and Peptide Hormones Work Together to Control Appetite and Fight Obesity

Three gut peptide hormones — CCK, GLP-1, and PYY — serve as the primary signaling molecules in the satiety system, released by enteroendocrine cells (EECs) in response to specific macronutrients detected through nutrient-sensing receptors. The gut microbiota directly interacts with EECs and modulates hormone release by changing the gut environment and producing metabolites. Diet shapes the microbiome, which shapes hormone release, which shapes brain appetite signals — creating the microbiota-gut-brain axis (MGBA). The review proposes that bioactive compounds exploiting these nutrient-sensing mechanisms could become functional foods or drugs for obesity.

Narrative review covering the biology of gut peptide satiety hormones (CCK, GLP-1, PYY), enteroendocrine cell nutrient-sensing mechanisms, the role of the intestinal microbiota in modulating these systems, and the microbiota-gut-brain axis. Also discusses organ-on-a-chip technology as a platform for modeling multi-organ communication and testing potential bioactive compounds.

Obesity affects over 650 million adults worldwide and current treatments are limited. Understanding the natural signaling system that controls appetite — from the food we eat to the bacteria in our gut to the hormones that tell our brain we're full — reveals multiple intervention points. Rather than targeting a single receptor (as GLP-1 drugs do), future therapies could work through functional foods that optimize the entire microbiota-gut-brain axis.

The success of GLP-1 drugs has validated the gut peptide hormone approach to obesity treatment. This review zooms out to show that GLP-1 is just one part of a larger system involving multiple hormones, the gut microbiome, and dietary inputs. As the field moves toward combination peptide therapies (GLP-1 + GIP, or GLP-1 + PYY), understanding the full microbiota-gut-brain axis becomes essential. Functional foods that optimize this entire system could eventually complement or even replace some pharmaceutical interventions.

This is a broad conceptual review without new experimental data. Many proposed mechanisms are based on animal studies and may not translate to humans. The gut microbiome-satiety connection in humans is still poorly defined. Organ-on-a-chip technology is promising but not yet validated for predicting human appetite responses. The review doesn't address the practical challenges of designing functional foods with reliable bioactive compound delivery.